蛭蛇通络胶囊联合血栓通注射液治疗脑梗死恢复期临床评价

目的探讨蛭蛇通络胶囊联合血栓通注射液治疗脑梗死恢复期的临床疗效。方法选取医院2016年2月至2017年12月收治的脑梗死恢复期患者200例,按随机数字表法分为对照组(99例)和研究组(101例)。两组患者均给予血栓通注射液治疗,研究组患者加用蛭蛇通络胶囊治疗。两组均治疗4周。结果研究组总有效率为89. 11%,显著高于对照组的73. 74%(P <0. 05);治疗后,两组患者的中医症候积分均低于治疗前,且研究组低于对照组(P <0. 05);两组患者的高切还原黏度(HSRV)、全血黏度(WBV)、低切还原黏度(LSRV)、血液沉降率(ESR)、纤维蛋白原(FIB)及总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)均较治疗前降低(P <0. 05),且研究组患者的WBV,ESR,FIB及TC,TG,LDL-C均低于对照组患者(P <0. 05),但两组患者的高密度脂蛋白胆固醇(HDL-C)高于治疗前,且研究组高于对照组(P <0. 05);两组不良反应发生率相当(P> 0. 05)。结论蛭蛇通络胶囊联合血栓通注射液治疗脑梗死恢复期的临床疗效较好,可改善患者的中医症候积分、血液流变学及血脂水平,且安全性较高。

Zhishetongluo Capsule Combined with Xueshuantong Injection in the Treatment of Cerebral Infarction in Convalescent Stage

Objective To investigate the clinical efficacy of Zhishetongluo Capsule combined with Xueshuantong Injection in the treatment of cerebral infarction in convalescent stage. Methods A total of 200 patients with cerebral infarction in convalescence stage who were treated in the hospital from February 2016 to December 2017 were selected and divided into the control group( 99 cases) and the study group( 101 cases) according to the random number table method. The control group was treated with Xueshuantong Injection,while the study group was treated with Zhishetongluo Capsule on the basis of the control group. Both groups were treated for 4 weeks. Results The total clinical effective rate of the study group was 89. 11%,which was significantly higher than 73. 74% of the control group( P < 0. 05). After treatment,the scores of traditional Chinese medicine( TCM) symptoms in both groups was lower than those before treatment,and those in the study group was lower than those in the control group( P < 0. 05);the high shear reduction viscosity( HSRV),whole blood viscosity( WBV),low shear reduction viscosity( LSRV),blood sedimentation rate( ESR) and fibrinogen( FIB) in the two groups was lower than those before treatment( P < 0. 05),and the WBV,ESR and FIB in the study group was lower than those in the control group( P < 0. 05). After treatment,total cholesterol( TC),triglyceride( TG),low density lipoprotein( LDL-C)in the two groups were lower than those before treatment,and those in the study group were lower than those in the control group( P < 0. 05);the high density lipoprotein( HDL-C) levels in the two groups was higher than those before treatment,and that in the study group was higher than that in the control group( P < 0. 05). There was no significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Zhishetongluo Capsule combined with Xueshuantong Injection has better clinical efficacy in the treatment of cerebral infarction in convalescent stage. It can improve the TCM syndrome score,hemorheology and blood lipid level of patients,and it has a higher safety.